This website is for UK Healthcare Professionals only

Post-stroke spasticity (PSS) has a significant impact on daily life5,6

In a prospective cohort study of patients after a first ischaemic stroke, when 211 patients were assessed after 6 months,


had developed spasticity.6

PSS has a significant impact on a stroke survivor’s daily life, impeding basic tasks, such as eating and self-care5,7,8 

Intermittent or sustained involuntary activation of muscles5

Psychological consequences such as poor self-esteem and self image7

Interference with balance and movement, including decline in ability to walk5,8

Potential inability to perform activities of daily living and limit ability to engage in activities outside the home8

Increased rate of fractures as a consequence of increased risk of falls8

PSS: post-stroke spasticity.

BOTOX® (botulinum toxin type A) is indicated for the treatment of focal spasticity including:9

  • wrist and hand disability due to upper limb spasticity associated with stroke in adults
  • ankle and foot disability due to lower limb spasticity associated with stroke in adults



  1. Allergan. Data on file. INT/0423/2016
  2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
  3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
  4. Allergan. Data on file. 014
  5. Kheder A, Nair K P. Spasticity: pathophysiology, evaluation and management. Pract Neurol 2012;12(5):289-298
  6. Urban P P, Wolf T et al. Occurence and clinical predictors of spasticity after ischemic stroke. Stroke 2010;41(9):2016-2020
  7. Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines, March 2018. Available at: Accessed October 2022
  8. Esquenazi A. The human and economic burden of poststroke spasticity and muscle overactivity. JCOM 2011;18:607-614
  9. BOTOX® Summary of Product Characteristics. Available at: Accessed October 2022

Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.


Adverse events should be reported. Reporting forms and information can be found at or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

Adverse events should also be reported to AbbVie on [email protected] 


Date of preparation: October 2022. UK-BTX-220202.